Fresh Equities
Raises
Research
About
Looking for more information?

Contact our responsive and friendly client services team any time.

IMMURON LIMITED

INVESTOR PRESENTATION - IMMURON LIMITED

ASX:IMC

IMMURON LIMITED

Health Care

Immuron Ltd is an Australian biopharmaceutical company focused on oral immunotherapy utilizing polyclonal antibody products that target the human gut immune system and gut microbiome. Immuron’s technology platform is capable of developing and producing an orally stable therapeutic as a potential ‘oral targeted therapy’ for various immune mediated and inflammatory disorders, among them: non-alcoholic steatohepatitis (NASH) diabetes, colitis, inflammatory bowel diseases (IBD), irritable bowel syndrome (IBS), liver fibrosis and other chronic disorders in which the immune system plays a key role in pathogenesis. These disorders represent areas of growing and unmet medical need, where oral targeted therapy drugs could offer significant advantages due to the lack of absorption and the high safety profile.

Read more

Market Cap

58.27m

Price at Close

$0.26

4w avg. Volume

950.10k

4w avg. Turnover

$266.61k

Announcements
announcementt+2 movementdate
  • Change in substantial holding

    Shareholder Details

  • -3.77%

    18 Oct 2020

-3.77%

18 Oct 2020
  • Immuron Travelers Diarrhea Market Update

    Progress Report · Market sensitive

  • -15.38%

    12 Oct 2020

-15.38%

12 Oct 2020
  • Time of AGM Clarification

    Notice Of Meeting

  • 0.00%

    30 Sep 2020

0.00%

30 Sep 2020
  • Notice of Annual General Meeting/Proxy Form

    Notice Of Meeting

  • -9.26%

    25 Sep 2020

-9.26%

25 Sep 2020
  • Corporate Governance Statement

    Periodic Reports

  • -9.26%

    25 Sep 2020

-9.26%

25 Sep 2020
  • Appendix 4G

    Periodic Reports

  • -9.26%

    25 Sep 2020

-9.26%

25 Sep 2020
  • Annual Report to shareholders

    Periodic Reports

  • -9.26%

    25 Sep 2020

-9.26%

25 Sep 2020
  • Change in substantial holding

    Shareholder Details

  • -8.20%

    15 Sep 2020

-8.20%

15 Sep 2020
  • Change in substantial holding

    Shareholder Details

  • -5.00%

    03 Sep 2020

-5.00%

03 Sep 2020
  • Appendix 4E and 2020 Financial Report

    Periodic Reports · Market sensitive

  • -12.12%

    31 Aug 2020

-12.12%

31 Aug 2020
Market Data

Current Price

$0.26

52WK HIGH

$0.95

52WK LOW

$0.05

1YR RETURN

+108.00%

1YR RETURN VS. SECTOR

+88.10%

90 DAY RETURN

-34.18%

ASX RANK

997

/2,014

SECTOR RANK

24

/47

SHARES OUTSTANDING

224.10m
ASX:IMC

IMMURON LIMITED

Health Care

Immuron Ltd is an Australian biopharmaceutical company focused on oral immunotherapy utilizing polyclonal antibody products that target the human gut immune system and gut microbiome. Immuron’s technology platform is capable of developing and producing an orally stable therapeutic as a potential ‘oral targeted therapy’ for various immune mediated and inflammatory disorders, among them: non-alcoholic steatohepatitis (NASH) diabetes, colitis, inflammatory bowel diseases (IBD), irritable bowel syndrome (IBS), liver fibrosis and other chronic disorders in which the immune system plays a key role in pathogenesis. These disorders represent areas of growing and unmet medical need, where oral targeted therapy drugs could offer significant advantages due to the lack of absorption and the high safety profile.

Read more

Market Cap

58.27m

Price at Close

$0.26

4w avg. Volume

950.10k

4w avg. Turnover

$266.61k

ASX:IMC is not raising right now

Want to invest?

Fresh Equities

Copyright © 2020 Fresh Equities. All rights reserved. ACN 619 657 028. CAR: 001267539 of AFSL: 471379.

Contact Us

(03) 9028 2888

clients@freshequities.com

Address

Level 7, 388 Bourke St
Melbourne VIC 3000
Australia

Copyright © 2020 Fresh Equities. All rights reserved. ACN 619 657 028. CAR: 001267539 of AFSL: 471379.